As Semaglutide is now on most formularies, ABCD would like to encourage you to join in the nationwide audit. Semaglutide has been shown to be more effective than other GLP-1 receptor agonists, both at improving HbA1c and reducing weight. But there are many unanswered questions for example:
- How great is the impact of Semaglutide when patients are switched from another GLP-1 receptor agonist
- In our previous audits with GLP-1 receptor agonists the higher the weight and HbA1c the bigger the fall. It will be of considerable interest to see how great will be the impact of Semaglutide in the much heavier more poorly controlled patients who are likely to receive it than in the clinical trials.
- Are there any factors that will predict good response and poor response
- What will be the impact on insulin requirement
It is easy to analyse your own results in the on-line ABCD semaglutide audit tool as shown in the how to do it video tutorial. Some CCGs are requesting local audit and the tool facilitates this.
Forms for handwritten data entry that exactly match the online tool can be downloaded from the semaglutide audit webpage, where you can register for the audit and access the on-line tool.
You do not have to be a member of ABCD to join the audit which is open to all users of semaglutide and local data analysis is an appropriate project for medical students, junior doctors and diabetes specialist nurses.
As we have done with previous audits, all contributors will be acknowledged in all papers and presentations from the audit data and biggest contributors will be offered the possibility of being co-authors.
ABCD looks forward to welcoming you to the audit. For more information please contact the ABCD nationwide audits database administrator, Melissa Cull.
With best wishes on behalf of ABCD
Dr Bob Ryder MD. FRCP.
Clinical lead, ABCD audits of new diabetes therapies and devices
Consultant Diabetologist
City Hospital
Dudley Road
Birmingham B18 7QH
